MENA Fabry Disease Treatment Market Projections Show US$ 295.32 Million With a Remarkable 5.8% CAGR From 2025 to 2034

The MENA Fabry disease treatment market size was valued at USD 167.76 million in 2024. With a CAGR of 5.8% during 2025-2034, the market is projected to grow to USD 295.32 million by 2034.

Market Introduction:
Fabry disease treatment focuses on addressing the underlying enzyme deficiency and managing the wide range of symptoms caused by this inherited lysosomal storage disorder. The disease occurs due to a deficiency or malfunction of the alpha-galactosidase A enzyme, which leads to the accumulation of a fatty substance called globotriaosylceramide (GL-3) within the body's cells. The cornerstone of treatment is enzyme replacement therapy (ERT). In ERT, patients receive regular infusions of a synthetic version of the missing enzyme to help clear GL-3 buildup and slow the progression of organ damage. Another option for certain patients with amenable gene mutations is chaperone therapy. Cheaperone therapy uses a small-molecule drug to stabilize and enhance the activity of the body's own faulty enzyme.

Get Exclusive Sample Pages of This Report:
https://www.polarismarketresearch.com/industry-analysis/middle-east-north-africa-mena-fabry-disease-treatment-market/request-for-sample

Market Dynamics:
Improved Genetic Testing Infrastructure:
Investments in additional diagnostic facilities across the MENA are expanding access to advanced genetic testing for rare diseases, such as Fabry. Several governments are prioritizing early detection by equipping labs and hospitals with the capability to perform precise gene analysis. Collaborations between regional health authorities and global health firms help streamline the transfer of technology and training for local professionals.

Growth in Health Insurance Penetration:
There has been a notable expansion of healthcare insurance across major MENA economies, including Qatar, the UAE, and Saudi Arabia. For instance, the 2024 Healthcare Statistics for Saudi Arabia, published by the General Authority for Statistics, indicated that 100% of Saudi citizens had healthcare coverage. Public and private insurers are increasingly offering reimbursement for high-cost treatments. This shift has made treatment increasingly accessible for patients who can't bear the financial burden. Thus, the growth in health insurance penetration is contributing to the development of the MENA Fabry disease treatment market.

Market Key Players:
The rising number of product launches and robust market expansion strategies shape the competitive landscape of the market.

A few of the key MENA Fabry disease treatment market players include:

List of Key Companies with Approved Drugs:
• Chiesi Farmaceutici S.p.A.
• JCR Pharmaceuticals Co., Ltd.
• Protalix BioTherapeutics Inc.
• Sanofi
• Takeda Pharmaceutical

List of Companies with Drugs Under Clinical Trial Phase:
• Amicus Therapeutics, Inc.
• Idorsia Pharmaceuticals Ltd.
• Idorsia Pharmaceuticals Ltd.
• ISU ABXIS Co., Ltd.
• Sangamo Therapeutics, Inc.

Request for a Discount on this Report Before Purchase:
https://www.polarismarketresearch.com/industry-analysis/middle-east-north-africa-mena-fabry-disease-treatment-market/request-for-discount-pricing

MENA Fabry's Disease Treatment Market Report Highlights:
• By route of administration, in 2024, the intravenous route segment was valued at USD 110 million. The segment growth is attributed to the established use of enzyme replacement therapies (ERTs) that require infusion-based delivery

• Based on therapy, in 2024, the enzyme replacement therapy (ERT) segment was valued at approximately USD 115 million. The demand for ERT is driven by its status as the most established therapeutic approach for Fabry's disease.

• The Saudi Arabia Fabry's disease treatment market accounts for approximately 31% of the total regional revenue share, driven by the government's strong investments in rare disease care.

• The Egypt Fabry's disease treatment market is projected to register a CAGR of 6.2% from 2025 to 2034, largely fueled by improved diagnostic capacity and greater public-private collaboration.

Explore The Complete Comprehensive Report Here:
https://www.polarismarketresearch.com/industry-analysis/middle-east-north-africa-mena-fabry-disease-treatment-market

Market Segmentation:
The market is primarily segmented based on route of administration, therapy, and distribution channel.
Based on route of administration, the intravenous route segment led the market in 2024. The segment's dominance is primarily attributed to the established use of ERT, which requires infusion-based therapy. Hospitals and specialty clinics in the region are increasingly equipped to administer IV treatments, offering controlled environments and trained staff to manage infusion protocols.

By therapy, the substrate reduction therapy segment is projected to register a significant CAGR from 2025 to 2034. The segment's robust growth is driven by increasing clinical adoption and rising patient preference for oral treatment regimens. In addition, rising physician awareness of substitute therapy has led to more personalized treatment strategies that integrate SRT where appropriate.
By Route of Administration Outlook (Revenue USD Million, 2020-2034)
• Intravenous Route
• Oral Route

By Therapy Outlook (Revenue USD Million, 2020-2034)
• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Others

By Distribution Channel Outlook (Revenue USD Million, 2020-2034)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regional Assessment:
The MENA region presents untapped potential for Fabry disease treatment, driven by increasing disease awareness and gradual improvements in rare disease diagnostics. Saudi Arabia and Turkey lead with expanding healthcare infrastructure and research funding for orphan diseases. Iran and Egypt are witnessing growing adoption of enzyme replacement therapies due to evolving government healthcare policies. Algeria, Morocco, and Iraq show promise with ongoing pharmaceutical investments and partnerships. Libya and the Rest of MENA remain largely underserved, indicating strong opportunities for market entry through awareness campaigns and public-private collaborations.

More Trending Latest Reports by Polaris Market Research:
Digital Health For Obesity Market:
https://www.polarismarketresearch.com/industry-analysis/digital-health-for-obesity-market

Chatbot-Based Mental Health Apps Market:
https://www.polarismarketresearch.com/industry-analysis/chatbot-based-mental-health-apps-market

Cryoablation Probe Market:
https://www.polarismarketresearch.com/industry-analysis/cryoablation-probe-market

Surgical Helmet Market:
https://www.polarismarketresearch.com/industry-analysis/surgical-helmet-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.